- KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesion
- KEYTRUDA, in combination with lenvatinib, is indicated for the first-line treatment of advanced renal cell carcinoma in adults
- KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of advanced renal cell carcinoma in adults
Introduction
Please use the video selection tool on the left to navigate through the module.
Upon watching all videos there are some questions for you to reflect on, which should take around 20 minutes.
We estimate the module will take roughly an hour to complete, and upon completion (if logged in) a CPD certificate will become available and can be downloaded by clicking the CPD logo in the banner above.
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
The importance of collaboration in a uro-oncology MDT
Length: 8:51 | This video is best viewed in full screen, using the button in the bottom right
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Co-creating a treatment plan for patients with renal cell carcinoma, in a uro-oncology MDT
Length: 19:15 | This video is best viewed in full screen, using the button in the bottom right
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Managing diarrhoea with dose reduction and treatment interruption
Length: 02:42 | This video is best viewed in full screen, using the button in the bottom right
Prof. Tom Powles presents a case study of a 72 year old male who started on KEYTRUDA in combination with axitinib for advanced renal cell carcinoma, 18 months post nephrectomy. Prof. Powles explains the steps he took to manage the grade 1 diarrhoea.
Favourable
72
Male
1
Heavy smoker, osteoarthritis, controlled hypertension
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Managing transaminitis with steroids in a patient with intermediate risk advanced RCC
Length: 02:36 | This video is best viewed in full screen, using the button in the bottom right
Prof. Tom Powles presents a case study of a 32 year old female who started on KEYTRUDA in combination with axitinib, less than a year after an advanced renal cell carcinoma diagnosis. Prof. Powles explains how transaminitis was managed.
Intermediate
32
Female
1
Irritable bowel disease, 3 month history of haematurea
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Treatment of advanced RCC in a patient with liver and bone metastasis
Length: 02:06 | This video is best viewed in full screen, using the button in the bottom right
Prof. Tom Powles presents his treatment decision for a 45 year old male who started on KEYTRUDA in combination with axitinib, 6 months post nephrectomy for rapidly progressing advanced renal cell carcinoma.
Poor
45
Male
1
Nil of note (marathon runner)
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Questions for self-reflective learning
We encourage you to digest the content in the videos by reflecting on the following questions. We estimate this should take around 20 minutes.
Thinking about your own cross functional MDT, what opportunities are there for informal communication and reflective team learning?
How do you identify and manage adverse events with prescribing combination therapies?
How can clinicians support patients to recognise and report adverse events to ensure early intervention management and initiate adverse event protocols?
After reflection please remember to download your CPD certificate by clicking the logo in the banner above (you will need to login).
Adverse events should be reported. Adverse event reporting forms and information can be found at the bottom of this page.
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]